TABLE 3.
Demographic and clinical data in patients with an HBV DNA level of >105 copies/ml under entecavir or lamivudine treatment before bilirubin level reached >15 mg/dl
| Parameter | Value for group |
P | |
|---|---|---|---|
| Entecavir (n = 40) | Lamivudine (n = 59) | ||
| Age (yrs)a | 49 ± 14 | 40 ± 15 | 0.002 |
| Sex (M/Fb) | 27/13 | 43/16 | 0.654 |
| AST (U/liter)a | 890 ± 718 | 1,277 ± 1,243 | 0.079 |
| ALT (U/liter)a | 1,277 ± 752 | 1,826 ± 1,120 | 0.008 |
| Albumin (g/dl)a | 3.7 ± 0.6 | 3.5 ± 0.6 | 0.068 |
| Bilirubin (mg/dl)a | 5.6 ± 3.5 | 6.8 ± 3.7 | 0.088 |
| Creatinine (mg/dl)a | 0.9 ± 0.2 | 0.9 ± 0.2 | 0.606 |
| Prothrombine time (INR)a | 1.4 ± 0.4 | 1.4 ± 0.4 | 0.292 |
| Platelet (cells × 109 /ml)a | 150 ± 55 | 164 ± 49 | 0.188 |
| HBeAg (positive/negative) | 13/27 | 29/30 | 0.147 |
| HBV DNA (×105copies/ml)a | 1,809 ± 3,747 | 2,311 ± 5,358 | 0.609 |
a
Data presented as means ± standard deviations.
b
M, male; F, female.